Comparison of effects of aspirin and indomethacin on human platelet prostaglandin synthetase

D. CROOK AND A. J. COLLINS

From the Pharmacology Department, School of Pharmacy and Pharmacology, University of Bath, and the Arthritis and Rheumatism Research Unit, Royal National Hospital for Rheumatic Diseases, Bath

SUMMARY Human platelets were incubated in vitro with either aspirin or indomethacin and the prostaglandin synthetase activity of the resultant microsomal fraction from each incubation measured using a radiometric technique. Whereas aspirin produced a dose-related inhibition of the enzyme, indomethacin produced little or no inhibition over the same concentration range (10⁻⁶ mol/l–10⁻⁸ mol/l). Furthermore, administration of aspirin (600 mg) to volunteers produced a highly significant, prolonged inhibition of platelet microsomal prostaglandin synthetase whereas no inhibition was found with indomethacin (50 mg). As indomethacin is considerably more potent than aspirin as an inhibitor of human platelet prostaglandin synthetase in vitro, the results suggest a fundamental difference in the nature of the inhibition produced by each drug, aspirin being an essentially irreversible inhibitor whereas the inhibition produced by indomethacin is reversible. Studies with [³H-acetyl] aspirin have confirmed previous findings (Roth and Majerus, 1975) that aspirin produces an irreversible acetylation of a particulate fraction protein from human platelets.

The hypothesis that aspirin-like drugs exert their various pharmacological actions via inhibition of prostaglandin (PG) biosynthesis (Vane, 1971) has received wide support from many experiments carried out on human and animal systems, both in vitro and in vivo (Flower, 1974). Little is known about the nature of this blockade of PG biosynthesis at the molecular level, however, though results obtained with the enzyme prepared from sheep seminal vesicular glands suggest that most of the common aspirin-like drugs, including indomethacin and aspirin itself, are ‘competitive-irreversible’ inhibitors (Smith and Lands, 1971; Ku and Wavary, 1973; Raz et al., 1973). Furthermore, the absence of intermediates from inhibited preparations suggests that these drugs block an early, possibly the initial, stage of PG synthesis (Tomlinson et al., 1972).

During the course of studies of the effects of aspirin and aspirin-like drugs on PG synthetase prepared from human rheumatoid synovial tissue, we have observed (Crook et al., 1976) that prolonged therapy with the commonly used aspirin-like drugs did not inhibit the in vitro activity of a microsomal fraction derived from this tissue; in contrast, aspirin therapy completely destroyed subsequent in vitro enzyme activity. In order to investigate this unexpected difference further, we have studied the effect of aspirin and indomethacin, both in vitro and in vivo, on PG synthetase prepared from human platelets. Our results show a distinct difference between the nature of the inhibition produced by these two drugs.

Materials and methods

Platelet-rich plasma was obtained from healthy volunteers by centrifugation of heparinized blood at 50 g for 10 minutes, then at 100 g for 10 minutes. A platelet pellet was obtained by centrifugation of the combined plasmas at 2500 g for 5 minutes.

Preparation of microsomal fraction

5 ml ice-cold Tris-acetate buffer (0.1 mol/l, pH 8.0) containing sucrose (0.25 mol/l), EDTA (1 mmol/l), hydroquinone (0.5 mmol/l), cysteine (1 mmol/l), and reduced glutathione (2 mmol/l) was added to each cell preparation. While maintained in ice the mixture was sonicated (Rapidis 300, Ultrasonics Ltd.) by two 30-second pulses of 200 watts. Cell debris and any unbroken cells were removed by centrifugation at 2500 g for 5 minutes, after which a microsomal fraction was obtained by centrifugation at 10⁶ g for 1 hour.
PRODUCTION OF $^{14}$C PG FROM $^{14}$C ARACHIDONIC ACID

Each microsomal pellet was resuspended in fresh buffer mixture by a brief period of sonication and incubated with $^{14}$C-arachidonic acid (100 nCi, final concentration 0.85 μmol/l) at 37°C for 1 hour, with shaking, in a volume of 2 ml. The reaction was terminated by the addition of 2 M citric acid (0.25 ml).

EXTRACTION, SEPARATION, AND QUANTITATION OF FORMED PGs

The formed $^{14}$C PGs and unconverted substrate were extracted from the acidified incubates with diethyl ether (2 x 3.0 ml). After evaporation of the combined extracts under nitrogen at 37°C the residue was dissolved in 20 μl chloroform/methanol, 2:1, and 5 μl applied to a thin layer plate (silica gel G, 0.25 mm, containing 2.5% silver nitrate). Authentic arachidonic acid, PGE$_2$, and PGF$_2α$ were applied in a marker lane and the plate developed in benzene-dioxan-acetic acid, 20 : 20 : 1 to a height of 15 cm.

After locating the markers with phosphomolybdic acid and scanning the plate for radioactivity, the zones in the extract lanes which corresponded to the markers were scraped from the plate and their activity determined by liquid scintillation counting, quench corrections being achieved using a channels ratio method.

INCUBATION OF WHOLE PLATELETS WITH ASPIRIN AND INDOMETHACIN

Aliquots of platelet-rich plasma were incubated with either aspirin or indomethacin over the concentration range 10$^{-6}$ mol/l—10$^{-5}$ mol/l, at 37°C for 30 minutes, with shaking. The platelet pellet obtained by centrifugation at 2500 g for 5 minutes was resuspended in Tyrode's solution (5·0 ml), incubated at 37°C for a further 10 minutes and the platelet pellet again obtained by centrifugation. The preparation of the microsomal fraction and measurement of PG synthetase activity were then carried out as described above.

INCUBATION OF PLATELET MICROSONES WITH ASPIRIN AND INDOMETHACIN

Human platelet microsomes were resuspended in Tyrode's solution and aliquots incubated with either aspirin or indomethacin over the concentration range 10$^{-6}$ mol/l—10$^{-5}$ mol/l, at 37°C for 30 minutes with shaking. The suspension was then layered on to Tris-acetate buffer (0·1 mol/l, pH 7·4) containing sucrone (0·25 mol/l) and a microsomal pellet obtained by centrifugation at 10$^5$ g for 1 hour. The PG synthetase activity of each microsomal pellet was then measured as described above.

EFFECT OF ASPIRIN AND INDOMETHACIN IN VIVO

Three healthy male volunteers who had received no medication of any kind for at least 2 weeks beforehand were given indomethacin (50 mg) orally, and blood samples obtained over the following 96 hours, including a pre-drug, basal sample. 3 weeks later the procedure was repeated with the subjects taking aspirin (600 mg). Platelet-rich plasma was prepared from each sample, a platelet count performed, and the PG synthetase activity of the microsomal fraction measured as described above, using a constant number of platelets from each subject. Plasma levels of indomethacin and salicylate were measured by standard techniques.

PROTEIN ESTIMATION

Microsomal protein concentrations were measured by the method of Lowry et al. (1951), using bovine serum albumin as standard.

PREPARATION OF [3H-ACETYL] ASPIRIN

Salicylic acid (2.5 mg) was dissolved in pyridine (2·0 ml, redistilled) and heated with 3H-acetic anhydride (25 mCi, specific activity 3500 mCi/mmol, Amersham) at 37°C for 3 hours. The solvent was evaporated under nitrogen and the product purified by thin layer chromatography (silica gel G, 0·25 mm, methanol washed; solvent system cyclohexanechloroform-acetic acid, 80 : 20 : 10). The radioactive aspirin band was transferred to a small sinter, eluted with redistilled ethanol (10 ml), and stored at −20°C. Chromatographic properties and absorption spectra of the product showed it to be identical to authentic acetylsalicylic acid.

POLYACRYLAMIDE GEL ELECTROPHORESIS OF ACETYLATED PG SYNTHETASE

This was carried out essentially as described by Roth and Majerus (1975). Platelet microsomes were incubated with [3H-acetyl] aspirin (60 μmol/l) in 0·1 mol/l Tris-acetate buffer, pH 7·4, at 37°C for 30 minutes. The suspension was then layered on to Tris-acetate buffer (0·1 mol/l, pH 7·4) containing sucrose (0·25 mol/l) and a pellet obtained by centrifugation at 10$^5$ g for 1 hour. This was solubilized using sodium dodecyl sulphate (SDS)/mercaptoethanol solution and aliquots run on 5% polyacrylamide gels in 0·1 mol/l phosphate buffer, pH 7·1, containing 0·2% SDS. Gels were sliced, digested with hydrogen peroxide, and counted for radioactivity. Quench corrections were made using an external standard ratio method.
Comparison of effects of aspirin and indomethacin on human platelet prostaglandin synthetase

When added to active microsomal preparations of human platelet PG synthetase, both aspirin and indomethacin produced the expected dose-related inhibition (Fig. 1). Calculated from the dose of each drug required to produce 50% inhibition of PG biosynthesis, and expressed on a molar basis, indomethacin was approximately 150 times more potent than aspirin. The production of PGE\textsubscript{2} and PGF\textsubscript{2α} was equally affected, and no evidence was found for 'selective' inhibition by either aspirin or indomethacin.

Preincubation of whole platelets with aspirin or indomethacin showed a marked difference between the two drugs (Fig. 2). Thus while exposure to aspirin at 10\textsuperscript{-4} mol/l was capable of producing 80–90% inhibition of PG synthetase, indomethacin had little or no effect, even 10\textsuperscript{-3} mol/l producing less than 10% inhibition of subsequent microsomal PG synthetase activity. The apparent stimulation of PG synthesis by aspirin at 10\textsuperscript{-6} mol/l is not readily explained, though similar phenomena have been reported in other systems (Brocklehurst and Dawson, 1974; Stone et al., 1975).

Preincubation of human platelet microsomes with
either aspirin or indomethacin confirmed the findings described above with whole platelets. Thus while aspirin produced a dose-related inhibition of PG synthetase activity of similar potency to that found when present in an incubation mixture containing platelet microsomes and $^{14}$C-arachidonic acid, indomethacin was considerably less potent than aspirin in producing inhibition of PG synthetase by pre-incubation (Fig. 3). As indomethacin is approximately 150 times more potent than aspirin as a PG synthetase inhibitor when present in an incubation mixture containing platelet microsomes and $^{14}$C-arachidonic acid (Fig. 1), these findings strongly suggest that indomethacin is a reversible inhibitor of human platelet PG synthetase.

Administration of aspirin (600 mg) to 3 volunteers produced a prompt fall in platelet microsomal PG synthetase activity to less than 15% of basal levels, and this blockade lasted for several days (Fig. 4).

The time course of the inhibition of platelet PG synthetase by aspirin is thus effectively a measure of platelet turnover. By contrast, ingestion of indomethacin (50 mg) produced no reduction of microsomal PG synthetase activity in 2 individuals, and in the third subject brought about a stimulation of activity which at 24 hours after the drug had been taken was more than twice the basal level.

Studies using $[^3$H-acetyl] aspirin of high specific activity support the results obtained with aspirin from both the in vitro and in vivo experiments described here, and confirm previous findings (Roth and Majerus, 1975). Fig. 5 shows a typical scan of the radioactivity incorporated into platelet particulate fraction protein and separated by polyacrylamide gel electrophoresis. Reference to a series of protein markers of known molecular weight showed that the labelled peak had a molecular weight of 81,000, and calculation of the amount of label incorporated was in agreement with the previously reported figure of 2000–3000 acetyl groups per platelet.

![Graph showing the effect of orally ingested aspirin and indomethacin on subsequent microsomal PG synthetase activity from human platelets.](image1)

**Fig. 4** Effect of orally ingested aspirin and indomethacin on subsequent microsomal PG synthetase activity from human platelets. 3 volunteers each took indomethacin (50 mg) orally. Blood samples were taken at intervals over the following 96 hours, platelets were prepared from each sample, and the PG synthetase activity of the microsomal fraction from each one measured as described in the text. 3 weeks later the procedure was repeated with the volunteers taking aspirin (600 mg). Means ± standard error are shown.

![Graph showing the time course of inhibition of platelet PG synthetase by aspirin.](image2)

**Fig. 5** Polyacrylamide/SDS gel electrophoresis of human platelet microsomes incubated with $[^3$H-acetyl] aspirin. Human platelet microsomes were incubated with $[^3$H-acetyl] aspirin (60 μmol/l) in 0.1 M tris-acetate buffer, pH 7.4, at 37° for 30 min. The microsomes were washed by centrifugation through tris-acetate buffer containing sucrose (0.25 mol/l) and the pellet obtained was solubilized using SDS/mercaptoethanol. An aliquot of this solution containing 170 μg protein was electrophoresed on 5%, polyacrylamide, the gel cut into 3 mm slices, digested with hydrogen peroxide, and the radioactivity in each slice measured by liquid scintillation counting. The molecular weight of the labelled peak was calculated to be 81,000.
**Discussion**

The ability of the aspirin-like drugs to inhibit platelet aggregation has been known for many years, and much compelling evidence now exists to suggest that this action is brought about by the blockade of the biosynthesis of PGs, their cyclic endoperoxide precursors, and the recently discovered thromboxanes (Smith and Willis, 1971; Willis, 1973; Hamberg et al., 1975). However, while the effect of orally ingested aspirin in inhibiting both platelet PG production and platelet aggregation lasts for several days, the affect of indomethacin is short-lived (Kocsis et al., 1973). As aspirin has a short half-life in vivo and sodium salicylate does not produce these effects, a fundamental difference in the modes of action of aspirin and indomethacin is indicated.

Such a finding has great practical importance in view of the interest that has centred around the clinical potential of the aspirin-like drugs as anti-thrombotic agents. Platelets contain little RNA or DNA and are capable of very limited de novo enzyme synthesis (Steiner, 1970). Hence a drug which causes irreversible inhibition of platelet PG synthetase would appear to be superior in this respect to one which can exert its effect only for as long as an adequate plasma concentration is maintained. The equivocal results obtained so far using aspirin, therefore, might not augur well for the possible efficacy of other aspirin-like drugs.

Furthermore, as platelets are a potential source of PG-like material at inflammatory foci (Glatt et al., 1974), the time courses of the inhibition of PG production by aspirin or indomethacin at such sites might also be expected to differ. However, it is difficult to draw any further conclusions from the findings presented here without a detailed knowledge of the turnover rates of PG synthetase from the different cells involved.

The finding that aspirin produces a rapid, saturable, irreversible acetylation of a platelet particulate fraction protein at low (30 μmol/l) concentrations provides convincing evidence that this may be its mode of action in blocking PG synthesis at the molecular level. Consideration of the structures of other aspirin-like drugs, however, suggests that this is unlikely to be a general property of this group of compounds, as most possess no labile functional group. Our results suggest that indomethacin probably does not function as a benzoylating agent in an analogous manner to aspirin, though it would clearly be of interest to investigate this possibility using suitably labelled indomethacin of high specific activity.

**References**


Comparison of effects of aspirin and indomethacin on human platelet prostaglandin synthetase.
D Crook and A J Collins

doi: 10.1136/ard.36.5.459

Updated information and services can be found at:
[http://ard.bmj.com/content/36/5/459](http://ard.bmj.com/content/36/5/459)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)